The U.S. dental bone graft substitute and other biomaterials market had a value of $589 million in 2022 and is projected to grow at a CAGR of 5.3% during the forecast period, reaching a value of over $847 million. The comprehensive report suite on the U.S. dental bone graft substitutes market comprises several segments, including dental bone graft substitutes, dental growth factors, dental barrier membranes, local antimicrobial periodontal treatments, and dental soft tissue regeneration, all of which together form the dental biomaterials market.
DATA TYPES INCLUDED IN THIS REPORT:
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Market Forecasts Until 2029 & Historical Data to 2019
- Competitive Analysis with Market Shares for Each Market Segment
- Market Drivers & Limiters
- Recent Mergers & Acquisitions
- COVID19 Impact on the DBGS Market in the US
- Disease Overviews & Demographic Information
- Company Profiles, Product Portfolios & SWOT for Top Competitors
U.S. DENTAL BONE GRAFT SUBSTITUTE MARKET TRENDS
The dental bone graft substitute market is closely linked to the growth of the dental implant and final abutment markets, with over half of dental implant procedures requiring bone grafting beforehand. The U.S. dental implant market is expected to see significant growth over the forecast period, which will in turn drive demand for dental bone graft substitutes. As the dental implant market continues to expand, so too will the demand for dental bone graft substitutes.
U.S. DENTAL BONE GRAFT SUBSTITUTE MARKET SHARE INSIGHTS
The dental bone graft substitute market in the U.S. is largely controlled by four main competitors: Geistlich, ZimVie, OraPharma and BioHorizons. The remainder of the market is made up of smaller competitors and various tissue banks that distribute primarily through various companies in the market.
Geistlich emerged as the leading player in the dental bone graft substitute and other biomaterials market, with significant market shares in the dental bone graft substitute, dental barrier membrane, and dental soft tissue regeneration segments. The company's focus on regenerating bone, cartilage, and tissue has given it a competitive edge in the market. In October 2022, Geistlich further solidified its position by acquiring Lynch Biologics and obtaining the rights to its GEM 21S® dental growth factor product. With only four dental growth factor products available in the U.S. market, this acquisition sets Geistlich apart and strengthens its presence in the dental bone graft substitute market.
MARKET SEGMENTATION SUMMARY
Dental Bone Graft Substitute Market | United States | 2023-2029 - Includes:
- Allograft, xenograft and synthetic material sub-segments.
Dental Barrier Membrane Market | United States | 2023-2029 - Includes:
- Resorbable and non-resorbable dental barrier membrane segments.
Dental Growth Factor Market | United States | 2023-2029 - Includes:
- Straumann's Emdogain®, Lynch Biologics' GEM 21S®, Medtronic's Infuse® and NuVasive's Osteocel® (distributed by ACE SOUTHERN).
- Local Antimicrobial Periodontal Treatment Market | United States | 2023-2029
Dental Soft Tissue Regeneration Market | United States | 2023-2029 - Includes:
- Dental soft tissue regeneration market and dental soft tissue wound care market segments.
RESEARCH SCOPE SUMMARY
- Regions : North America (United States)
- Forecast Period: 2023-2029
- Historical Data: 2019-2022
- Quantitative Data: Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices
- Qualitative Data: COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios
- Data Sources: Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.
WHY CHOOSE IDATA?
- Experts Only - iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavor never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.
- Global Coverage - iData's unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.
- Attention to Detail - It's our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.
- Pricing - When comparing like-with-like, iData's prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.